GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Degree of Operating Leverage

ENDV (Endonovo Therapeutics) Degree of Operating Leverage : 4.98 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Endonovo Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Endonovo Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 4.98. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Endonovo Therapeutics's Degree of Operating Leverage or its related term are showing as below:

ENDV's Degree of Operating Leverage is ranked worse than
86.25% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs ENDV: 4.98

Endonovo Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Endonovo Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Degree of Operating Leverage Chart

Endonovo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 2.49 4.05 8.16 -33.27

Endonovo Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.27 1.43 0.16 0.25 4.98

Competitive Comparison of Endonovo Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Endonovo Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Degree of Operating Leverage falls into.


;
;

Endonovo Therapeutics Degree of Operating Leverage Calculation

Endonovo Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -1.024 (Mar. 2025) / 0.268 (Mar. 2024) - 1 )/( 0.002 (Mar. 2025) / 0.061 (Mar. 2024) - 1 )
=-4.8209/-0.9672
=4.98***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Endonovo Therapeutics  (OTCPK:ENDV) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Endonovo Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an USA-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics Headlines

From GuruFocus

Endonovo Partners with International Distributor for SofPulse� Line

By Stock market mentor Stock market mentor 01-26-2023

Endonovo Targets Dept. of Defense, VA & Federal Contracts

By Stock market mentor Stock market mentor 01-03-2023

Endonovo Launches Telehealth Initiative

By Value_Insider Value_Insider 12-13-2022